New Search

If you are not happy with the results below please do another search

Generic filters

50 search results for:


China’s Sinovac to test coronavirus vaccine candidate in teenagers, children

Sinovac Biotech plans to start a clinical trial of the Chinese vaccine maker’s experimental coronavirus vaccine with children and adolescents in September, widening the company’s test on a shot that is already in the final stage of study with adults.


Moderna and Vertex Establish New Collaboration

Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).


Orphazyme’s Rare Lipid Disorder Drug Gets FDA Priority Review

The U.S. Food and Drug Administration accepted Copenhagen, Denmark-based Orphazyme’s New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C.


Reimagining Content for a COVID world: Ten Critical Dos and Don’ts for Brands

COVID-19 has dramatically altered many of the traditional means of communication and education in the medical community. As often happens in a major crisis, innovations have evolved at lightning speed. Healthcare audience outlooks and expectations have also taken permanent turns.


AstraZeneca’s trial illnesses may not be due to Covid-19 shot, Oxford University says

The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.


NIH Raises Concerns About Potential Safety Issues Associated with AstraZeneca Vaccine

The National Institutes of Health (NIH) raised concern about the safety of AstraZeneca’s coronavirus vaccine as the U.S. Food and Drug Administration is weighing whether or not to resume testing in the United States following a global pause in the Phase III trial for safety reasons.